Clinical Trials Browser

Phase 2/3 × netupitant × Clear all

NCT03040726 2023-10-17

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

Phase 2/3 Completed

53 enrolled 15 charts

Nausea, Neoplasms, Vomiting